Cannabis Law Report

MAY 26, 2021

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have… Read More.

Clinical Trials 98

Clinical Trials 98

Cannabis Life Network

NOVEMBER 18, 2020

announced early this morning that it will undertake a clinical trial of psilocybin-assisted psychotherapy. The compassionate access clinical trial will enable the company to refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders.

Clinical Trials 96

Clinical Trials Cannabis Access Therapy 96

Veriheal

JUNE 17, 2021

However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinical trial for cannabis as a migraine treatment is underway. The First Clinical Trial for Migraines and Cannabis.

Clinical Trials 81

Clinical Trials Cannabis Treatment Patients 81

Cannabis Law Report

JANUARY 11, 2023

PRESS RELEASE UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.

Clinical Trials 52

Clinical Trials CBD Cannabinoids Pharmaceutical 52

Cannabis Law Report

JULY 21, 2021

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. Tryp expects to submit the Investigational New Drug (IND) application to the FDA for the Phase 2a clinical trial in 3Q 2021. San Diego, California–(Newsfile Corp.

Clinical Trials 105

Clinical Trials Chronic Pain Treatment Research and Development 105

Veriheal

JANUARY 5, 2023

The post Clinical Trial Explores CBD’s Influence on Cannabis Safety appeared first on Cannabis Central.

Clinical Trials 74

Clinical Trials Cannabis Safety CBD 74

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. SOURCE Wake Network, Inc.

Clinical Trials 104

Clinical Trials Cannabis Therapy Medicine 104

Cannabis Law Report

FEBRUARY 27, 2022

“Securing Clinical Trial Authorisation solidifies over 16 months of hard work and dedication from our team and positions Halucenex as one of very few Canadian companies with approval to commence a clinical trial utilising psychedelic substances on mental health conditions,” president, CEO and founder Bill Fleming said.

Clinical Trials 52

Clinical Trials Treatment Conditions Data 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical CBD Research and Development 105

Cannabis Law Report

FEBRUARY 22, 2021

The post Psychedelic Clinical Trials & Who’s Behind Them first appeared on Cannabis Law Report. CFN report… The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging… Read More.

Clinical Trials 52

Clinical Trials Cannabis Law 52

Cannabis Law Report

JUNE 7, 2021

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials THC Patients Cannabinoids 105

Cannabis Law Report

APRIL 28, 2023

(“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary […] (..)

Clinical Trials 52

Clinical Trials Pharmaceutical Patients Business 52

Cannabis Law Report

JANUARY 17, 2021

The post NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials first appeared on Cannabis Law Report. We hope he does a better job than some of the playlists we’ve seen recently ! NeonMind Biosciences Inc. … Read More.

Clinical Trials 97

Clinical Trials Programs Cannabis Law 97

Cannabis Law Report

SEPTEMBER 2, 2022

The clinical trial involving the use of Filament’s psilocybin received approval from Health Canada and was conducted as part of ATMA Journey Centre’s psychedelic-assisted therapist training program. Filament administers psilocybin to 14 participants in Health Canada sanctioned clinical trial.

Clinical Trials 52

Clinical Trials Therapy Legalization Medicine 52

Cannabis Law Report

MAY 11, 2021

Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial. VANCOUVER, BC, May 11, 2021 /CNW/… Read More.

Clinical Trials 93

Clinical Trials Extraction Cannabis 93

NORML

MAY 21, 2019

The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry.

CBD 196

CBD Clinical Trials Cannabis Marijuana 196

Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Project CBD

JANUARY 1, 2022

New studies highlight therapeutic potential of cannabinoids for cancer, but clinical trials are lacking.

Clinical Trials 362

Clinical Trials Cannabinoids 362

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com. 310.299.1717 Office.

Clinical Trials 89

Clinical Trials Chronic Pain Cannabis Patients 89

Medical Marijuana Program Connection

FEBRUARY 28, 2023

Incannex Healthcare Limited IXHL IHL has commenced a phase 2 clinical trial to assess the safety and efficacy of its. Read More

Clinical Trials 40

Clinical Trials CBD Treatment Safety 40

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board. Research in the area of mental health has been Dr. Nitin Desai’s passion. ” About Ehave, Inc.

Clinical Trials 105

Clinical Trials Research and Development Patients Law 105

Cannabis Law Report

OCTOBER 26, 2021

The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.

Clinical Trials 52

Clinical Trials Sleep Medicine Cannabis 52

Cannabis Law Report

DECEMBER 13, 2020

Clinical trials on the hallucinogenic drug DMT for the treatment of depression are expected to start in January. The post UK: Imperial College Of London To Study DMT In First-Ever Clinical Trial first appeared on Cannabis Law Report. Yahoo Finance Reports. According to The Guardian … Read More.

Clinical Trials 72

Clinical Trials Cannabis Treatment Law 72

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Collectively, between the two organizations we offer a full-service package from protocol development to timely and successful clinical trial execution.”.

Clinical Trials 98

Clinical Trials Cannabis Medicine Research and Development 98

NORML

JULY 25, 2022

The Act provides the office of the US Attorney General with a 60-day timeline to either approve or deny the applications from scientists wishing to engage in clinical trials involving the use of cannabis by human subjects.

Legislation 226

Legislation Cannabis Clinical Trials 226

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 84

Clinical Trials Pharmaceutical Cannabinoids Research and Development 84

Cannabis Law Report

JANUARY 18, 2023

SAN FRANCISCO–(BUSINESS WIRE)–#GPCR–Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced that it has entered into the clinical trial collaboration (..)

Clinical Trials 52

Clinical Trials Therapy Business 52

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Treatment Therapy Medicine 52

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Patients THC 52

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The post Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD appeared first on SpeedWeed. Image via.

Clinical Trials 52

Clinical Trials Therapy DEA Treatment 52

Cannabis Law Report

MARCH 30, 2019

Japanese officials approve Epidiolex for clinical trials. In Japan, there are approximately 3,000 patients who suffer from Dravet Syndrome, and some 4,300 afflicted with Lennox-Gastaut.

Clinical Trials 45

Clinical Trials Epilepsy Cannabis Pharmaceutical 45

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials THC Patients Cannabinoids 52

NORML

DECEMBER 18, 2020

This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.". “This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD.

Cannabis 246

Cannabis Patients Clinical Trials Dispensary 246

Cannabis Law Report

SEPTEMBER 26, 2022

is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. The first two cohorts were challenged with 21 mg of THC, dosed orally (twice the THC dose used in Part A). Anebulo Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Cannabinoids Pharmaceutical THC 52

SpeedWeed

FEBRUARY 18, 2021

The post Clinical Trial Shows Association Between Cannabis Inhalation and Improvement in Ulcerative Colitis appeared first on SpeedWeed. At least in the short term, it has proven to be effective in treating UC. View original article.

Clinical Trials 52

Clinical Trials Cannabis THC Patients 52

Cannabis Law Report

NOVEMBER 30, 2022

.–(BUSINESS WIRE)–ANANDA Scientific Inc.,

Clinical Trials 52

Clinical Trials Treatment CBD Pharmaceutical 52

Project CBD

MARCH 2, 2020

Recently NIDA supported a clinical trial which used nicotine as a therapy for relatively mild cannabis withdrawal symptoms.

Clinical Trials 280

Clinical Trials Cannabis Recreational Therapy 280